Vinmec Research Institute of Stem Cell and Gene Technology (VRISG), Vinmec Healthcare system, Hanoi, 458 Minh Khai, Hanoi 10000, Vietnam.
College of Health Sciences, VinUniversity, Hanoi, Vinhomes Ocean Park, Hanoi 10000, Vietnam.
Int J Mol Sci. 2020 Mar 6;21(5):1834. doi: 10.3390/ijms21051834.
(1) Background: Dendritic cell (DC) vaccination has shown outstanding achievements in cancer treatment, although it still has some adverse side effects. Vaccination with DC-derived exosomes has been thought to overcome the side effects of the parental DCs. (2) Method: We performed the experiments to check the ability of cryopreserved umbilical cord blood mononuclear cell-derived DCs (cryo CBMDCs) and their exosomes to prime allogeneic T cell proliferation and allogeneic peripheral blood mononuclear cell (alloPBMCs) cytotoxicity against A549 lung cancer cells. (3) Results: We found that both lung tumor cell lysate-pulsed DCs and their exosomes could induce allogeneic T cell proliferation. Moreover, alloPBMCs primed with tumor cell lysate-pulsed DCs and their exosomes have a greater cytotoxic activity against A549 cells compared to unprimed cells and cells primed with unpulsed DCs and their exosomes. (4) Conclusion: Tumor cell lysate-pulsed DCs and their exosomes should be considered to develop into a novel immunotherapeutic strategy-e.g., vaccines-for patients with lung cancer. Our results also suggested that cryo umbilical cord blood mononuclear cells source, which is a readily and available source, is effective for generation of allogeneic DCs and their exosomes will be material for vaccinating against cancer.
(1) 背景:树突状细胞 (DC) 疫苗在癌症治疗方面取得了显著成就,尽管它仍存在一些不良反应。用 DC 衍生的外泌体进行疫苗接种被认为可以克服亲本 DC 的副作用。(2) 方法:我们进行了实验,以检查冷冻保存的脐血单个核细胞衍生的 DC(cryo CBMDC)及其外泌体刺激异基因 T 细胞增殖和异基因外周血单个核细胞(alloPBMC)对 A549 肺癌细胞的细胞毒性的能力。(3) 结果:我们发现,肺肿瘤细胞裂解物脉冲 DC 及其外泌体均可诱导异基因 T 细胞增殖。此外,与未经预处理的细胞和未经脉冲 DC 及其外泌体预处理的细胞相比,用肿瘤细胞裂解物脉冲 DC 及其外泌体预处理的 alloPBMC 对 A549 细胞具有更强的细胞毒性。(4) 结论:肿瘤细胞裂解物脉冲 DC 及其外泌体可被视为开发针对肺癌患者的新型免疫治疗策略,例如疫苗。我们的结果还表明,冷冻脐血单个核细胞来源是一种易于获得的来源,可有效产生异基因 DC,其外泌体将成为癌症疫苗接种的材料。